From Yahoo Finance: 2025-05-30 11:28:00

Analyst Brian Abrahams maintains an Outperform rating and $943 price target for Regeneron Pharmaceuticals (REGN) as the company awaits results from a phase III study on itepekimab, a potential treatment for COPD.

Abrahams is optimistic about itepekimab’s ability to reduce COPD episodes, estimating a global peak revenue of $6 billion. Positive trial results could boost Regeneron’s stock by 5-15%, diverting attention from concerns about the depletion of other medicines like Eylea.

Though Regeneron shows growth potential, some believe other AI stocks offer higher returns with limited risk. For those seeking AI stocks with significant upside potential, consider alternatives to REGN.

No disclosures were reported in relation to the article.

Read more: RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results